key: cord-0850580-jfjc7wjb
authors: Haroun-Díaz, Elisa; de la Torre, María Vázquez; Ruano, Francisco Javier; Somoza Álvarez, Maria Luisa; Alzate, Diana Pérez; González, Paula López; Prieto-Moreno, Ana; Rojas, Isabel Torres; Cervera García, María Desamparados; Blanca-López, Natalia; Díez, Gabriela Canto
title: SEVERE ASTHMA DURING THE COVID-19 PANDEMIC: CLINICAL OBSERVATIONS
date: 2020-06-27
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2020.06.033
sha: 4795899d85d00776b6ea5510bd5bff3f6f63d54b
doc_id: 850580
cord_uid: jfjc7wjb

nan

In Spain, 2% of public health expenditures are devoted to asthma-related care (4). It is 110 estimated that the global economic burden of asthma is between 1.5 and 3 billion euros 111 annually, and higher costs are associated with greater disease severity (5).

Severe asthma affects 3.9% of asthmatic patients (5). It is defined as an inflammatory 113 chronic respiratory disease that remains uncontrolled despite optimal therapy and 114 treatment of contributing factors, or which worsens when high-dose treatment is 115 decreased (6). Around 50% of patients with severe asthma experience uncontrolled or 116 partially controlled symptoms despite maximal treatment (5). These patients pose a 117 special challenge for care providers because of the extensive diagnostic testing and care 118 resources they require.

The aim of this study is to determine the prevalence and characterization of COVID-19 120 infection among patients with severe asthma according to ERS/ATS criteria who 121 presented to our allergy department during the COVID-19 pandemic. 

Epidemiological and 206 clinical characteristics of 99 cases of

China: a descriptive study

Risk factors for severity and 210 mortality in adult COVID-19 inpatients in Wuhan

Guía Española para el Manejo del Asma 4.4

ATS guidelines on definition, evaluation and treatment of 219 severe asthma

The 221 inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by 222 targeting viral NSP15

Abbreviations: CV risk factor, cardiovacular risk factor; NSAIDs, nonsteroidal anti-inflammatory drugs; BMI, body mass index; RF, respiratory frequency on admission (rpm: respiration per minute); O Sat (oxigen saturation) on admission; polymerase chain reaction; CRP, C-reactive protein; LDH, lactate dehydrogenase; N/A, non applicable.